ThromboGenics NV, which is commercialising intellectual property in-licensed from KU Leuven and the Flanders Institute of Biotechnology (VIB) as treatments for eye diseases, cardiovascular diseases and cancer, has raised €56 million through a private placement of 2,944,523 new shares.
The shares were priced at €19 per share, a very small 3 per cent discount on the previous closing price, and were admitted to listing on Euronext Brussels yesterday (8 December).
The new funds will be used by ThromboGenics to prepare for the commercialisation of its lead product microplasmin, in the treatment of retinal disease, in the US and Europe.
Patrik De Haes, CEO of ThromboGenics, said, “We are delighted to have raised this additional funding from a broad range of investors, including existing shareholders. We intend to use our newly enhanced financial position to invest in the highly focused team needed to commercialise our lead product, microplasmin, which has recently completed a very successful Phase III program in patients with vitreomacular adhesion.”
“The success of microplasmin, which we believe has the potential to transform the treatment of retinal disease, is key to our plans of becoming a profitable, integrated company focused on ophthalmic medicines.”